Shots:
The EC has granted ODD to ABO-101 for the treatment of primary hyperoxaluria
ABO-101 is being evaluated in an open-label global P-I/II (redePHine) study assessing safety, tolerability, PK/PD, & preliminary efficacy of a single dose of ABO-101 in pts with PH type 1
ABO-101 is a one-time, liver-directed gene-editing therapy that uses an Acuitas-licensed…
